The efficacy of gemfibrozil therapy for raising high density lipoprotein levels

Stephen Weis, B. J. Kudchodkar, M. B. Clearfield, Andras G. Lacko

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thirty subjects, 5 normotriglyceridemic (NTG) with low HDL cholesterol (HDL-C < 35 mg/dl) and 25 hypertriglyceridemic (HTG) with low and high HDL-C (HDL-C > 35 mg/dl) were selected for this study. They were treated with gemfibrozil (600 mg BID) for 12 weeks. In both groups, gemfibrozil significantly reduced serum TG levels (p < 0.005), yet HDL-C increased significantly only in HTG patients (p < 0.005). The changes in HDL-C levels were highly variable (-40 to 50%) and appeared to be dependent on the levels of serum TG achieved during treatment. Based on post-treatment serum TG, the HTG patients were divided into 2 groups. Group 1 with serum TG of <100 mg/dL and Group 2 with serum TG levels >100 mg/dl. Significant post treatment increases in HDL-C were seen only in Group 1 (p < 0.005). The two groups had similar pretreatment serum TG and HDL-C levels but the LDL-C was significantly higher in Group 1 (p <0.025). Pretreatment serum LDL-C also correlated positively with the increases in HDL-C during treatment (r=0.51, p <0.01, n=25). Consequently, the patients were divided into three groups based on their initial serum LDL-C levels (Group 1: LDL-C < 130 mg/dl, Group 2: LDL-C, 130-159 mg/dl and Group 3: LDL-C>160 mg/dl). The HDL-C levels increased significantly upon treatment only in Group 3. Pretreatment levels of serum TG and HDL-C were not significantly different among the three groups. Initial body weight (r = -0.43 p <0.025, n=30) and percent change in body weight during treatment (r=-0.47, p < 0.025, n=30) correlated negatively with the percent reduction in serum TG. The change in body weight also showed significant negative correlation with the changes in HDL cholesterol (r=- 0.48, p<0.25, n=30). We conclude that gemfibrozil is most effective in reducing serum triglycerides, LDL-C and increasing serum HDL-cholesterol in HTG patients who also have comparatively high initial LDL cholesterol levels (Fredrickson's type IIb phenotype). For effective improvement of HDL- cholesterol in most HTG patients, serum TG levels need to be lowered below 100 mg/dl. Furthermore, the benefit of gemfibrozil therapy may be significantly enhanced by weight loss during treatment.

Original languageEnglish
Pages (from-to)353-367
Number of pages15
JournalArtery
Volume19
Issue number6
StatePublished - 1 Jan 1992

Fingerprint

Gemfibrozil
HDL Lipoproteins
HDL Cholesterol
Serum
Body Weight Changes
Therapeutics
LDL Cholesterol
Weight Loss
Body Weight
Phenotype

Cite this

Weis, Stephen ; Kudchodkar, B. J. ; Clearfield, M. B. ; Lacko, Andras G. / The efficacy of gemfibrozil therapy for raising high density lipoprotein levels. In: Artery. 1992 ; Vol. 19, No. 6. pp. 353-367.
@article{4499d74ee1d44eed80166671a2066cb3,
title = "The efficacy of gemfibrozil therapy for raising high density lipoprotein levels",
abstract = "Thirty subjects, 5 normotriglyceridemic (NTG) with low HDL cholesterol (HDL-C < 35 mg/dl) and 25 hypertriglyceridemic (HTG) with low and high HDL-C (HDL-C > 35 mg/dl) were selected for this study. They were treated with gemfibrozil (600 mg BID) for 12 weeks. In both groups, gemfibrozil significantly reduced serum TG levels (p < 0.005), yet HDL-C increased significantly only in HTG patients (p < 0.005). The changes in HDL-C levels were highly variable (-40 to 50{\%}) and appeared to be dependent on the levels of serum TG achieved during treatment. Based on post-treatment serum TG, the HTG patients were divided into 2 groups. Group 1 with serum TG of <100 mg/dL and Group 2 with serum TG levels >100 mg/dl. Significant post treatment increases in HDL-C were seen only in Group 1 (p < 0.005). The two groups had similar pretreatment serum TG and HDL-C levels but the LDL-C was significantly higher in Group 1 (p <0.025). Pretreatment serum LDL-C also correlated positively with the increases in HDL-C during treatment (r=0.51, p <0.01, n=25). Consequently, the patients were divided into three groups based on their initial serum LDL-C levels (Group 1: LDL-C < 130 mg/dl, Group 2: LDL-C, 130-159 mg/dl and Group 3: LDL-C>160 mg/dl). The HDL-C levels increased significantly upon treatment only in Group 3. Pretreatment levels of serum TG and HDL-C were not significantly different among the three groups. Initial body weight (r = -0.43 p <0.025, n=30) and percent change in body weight during treatment (r=-0.47, p < 0.025, n=30) correlated negatively with the percent reduction in serum TG. The change in body weight also showed significant negative correlation with the changes in HDL cholesterol (r=- 0.48, p<0.25, n=30). We conclude that gemfibrozil is most effective in reducing serum triglycerides, LDL-C and increasing serum HDL-cholesterol in HTG patients who also have comparatively high initial LDL cholesterol levels (Fredrickson's type IIb phenotype). For effective improvement of HDL- cholesterol in most HTG patients, serum TG levels need to be lowered below 100 mg/dl. Furthermore, the benefit of gemfibrozil therapy may be significantly enhanced by weight loss during treatment.",
author = "Stephen Weis and Kudchodkar, {B. J.} and Clearfield, {M. B.} and Lacko, {Andras G.}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "19",
pages = "353--367",
journal = "Artery",
issn = "0098-6127",
number = "6",

}

Weis, S, Kudchodkar, BJ, Clearfield, MB & Lacko, AG 1992, 'The efficacy of gemfibrozil therapy for raising high density lipoprotein levels', Artery, vol. 19, no. 6, pp. 353-367.

The efficacy of gemfibrozil therapy for raising high density lipoprotein levels. / Weis, Stephen; Kudchodkar, B. J.; Clearfield, M. B.; Lacko, Andras G.

In: Artery, Vol. 19, No. 6, 01.01.1992, p. 353-367.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The efficacy of gemfibrozil therapy for raising high density lipoprotein levels

AU - Weis, Stephen

AU - Kudchodkar, B. J.

AU - Clearfield, M. B.

AU - Lacko, Andras G.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Thirty subjects, 5 normotriglyceridemic (NTG) with low HDL cholesterol (HDL-C < 35 mg/dl) and 25 hypertriglyceridemic (HTG) with low and high HDL-C (HDL-C > 35 mg/dl) were selected for this study. They were treated with gemfibrozil (600 mg BID) for 12 weeks. In both groups, gemfibrozil significantly reduced serum TG levels (p < 0.005), yet HDL-C increased significantly only in HTG patients (p < 0.005). The changes in HDL-C levels were highly variable (-40 to 50%) and appeared to be dependent on the levels of serum TG achieved during treatment. Based on post-treatment serum TG, the HTG patients were divided into 2 groups. Group 1 with serum TG of <100 mg/dL and Group 2 with serum TG levels >100 mg/dl. Significant post treatment increases in HDL-C were seen only in Group 1 (p < 0.005). The two groups had similar pretreatment serum TG and HDL-C levels but the LDL-C was significantly higher in Group 1 (p <0.025). Pretreatment serum LDL-C also correlated positively with the increases in HDL-C during treatment (r=0.51, p <0.01, n=25). Consequently, the patients were divided into three groups based on their initial serum LDL-C levels (Group 1: LDL-C < 130 mg/dl, Group 2: LDL-C, 130-159 mg/dl and Group 3: LDL-C>160 mg/dl). The HDL-C levels increased significantly upon treatment only in Group 3. Pretreatment levels of serum TG and HDL-C were not significantly different among the three groups. Initial body weight (r = -0.43 p <0.025, n=30) and percent change in body weight during treatment (r=-0.47, p < 0.025, n=30) correlated negatively with the percent reduction in serum TG. The change in body weight also showed significant negative correlation with the changes in HDL cholesterol (r=- 0.48, p<0.25, n=30). We conclude that gemfibrozil is most effective in reducing serum triglycerides, LDL-C and increasing serum HDL-cholesterol in HTG patients who also have comparatively high initial LDL cholesterol levels (Fredrickson's type IIb phenotype). For effective improvement of HDL- cholesterol in most HTG patients, serum TG levels need to be lowered below 100 mg/dl. Furthermore, the benefit of gemfibrozil therapy may be significantly enhanced by weight loss during treatment.

AB - Thirty subjects, 5 normotriglyceridemic (NTG) with low HDL cholesterol (HDL-C < 35 mg/dl) and 25 hypertriglyceridemic (HTG) with low and high HDL-C (HDL-C > 35 mg/dl) were selected for this study. They were treated with gemfibrozil (600 mg BID) for 12 weeks. In both groups, gemfibrozil significantly reduced serum TG levels (p < 0.005), yet HDL-C increased significantly only in HTG patients (p < 0.005). The changes in HDL-C levels were highly variable (-40 to 50%) and appeared to be dependent on the levels of serum TG achieved during treatment. Based on post-treatment serum TG, the HTG patients were divided into 2 groups. Group 1 with serum TG of <100 mg/dL and Group 2 with serum TG levels >100 mg/dl. Significant post treatment increases in HDL-C were seen only in Group 1 (p < 0.005). The two groups had similar pretreatment serum TG and HDL-C levels but the LDL-C was significantly higher in Group 1 (p <0.025). Pretreatment serum LDL-C also correlated positively with the increases in HDL-C during treatment (r=0.51, p <0.01, n=25). Consequently, the patients were divided into three groups based on their initial serum LDL-C levels (Group 1: LDL-C < 130 mg/dl, Group 2: LDL-C, 130-159 mg/dl and Group 3: LDL-C>160 mg/dl). The HDL-C levels increased significantly upon treatment only in Group 3. Pretreatment levels of serum TG and HDL-C were not significantly different among the three groups. Initial body weight (r = -0.43 p <0.025, n=30) and percent change in body weight during treatment (r=-0.47, p < 0.025, n=30) correlated negatively with the percent reduction in serum TG. The change in body weight also showed significant negative correlation with the changes in HDL cholesterol (r=- 0.48, p<0.25, n=30). We conclude that gemfibrozil is most effective in reducing serum triglycerides, LDL-C and increasing serum HDL-cholesterol in HTG patients who also have comparatively high initial LDL cholesterol levels (Fredrickson's type IIb phenotype). For effective improvement of HDL- cholesterol in most HTG patients, serum TG levels need to be lowered below 100 mg/dl. Furthermore, the benefit of gemfibrozil therapy may be significantly enhanced by weight loss during treatment.

UR - http://www.scopus.com/inward/record.url?scp=0026448847&partnerID=8YFLogxK

M3 - Article

C2 - 1471924

AN - SCOPUS:0026448847

VL - 19

SP - 353

EP - 367

JO - Artery

JF - Artery

SN - 0098-6127

IS - 6

ER -